IMVT Overview
Upcoming Projects (IMVT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IMVT)
-
A Second Look: Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: IMVT, ROIV
Executed On: Feb 21, 2024 at 01:15 PM EST -
A third Look: Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: IMVT, ROIV
Executed On: Jan 19, 2024 at 09:00 AM EST -
Discussing the potential of Roivant's batoclimab for normalizing of T3 and T4 hormone levels in patients with Graves’ disease
Tickers: ROIV, IMVT
Executed On: Jan 17, 2024 at 07:00 PM EST -
A Second Take: Discussing targets in TED (IGF-1R, IL-6 & FcRn class), including their available clinical data.
Tickers: HZNP, VRDN, IMVT, ARGX
Executed On: Sep 19, 2023 at 09:45 AM EDT -
Discussing targets in TED (IGF-1R, IL-6 & FcRn class), including their available clinical data.
Tickers: HZNP, VRDN, IMVT, ARGX
Executed On: Sep 18, 2023 at 07:30 PM EDT -
Exploring the TED treatment landscape with an ophthalmologist focusing on Horizon's Tepezza (teprotumumab-trbw), Immunovant's Batoclimab (IMVT-1401), and Viridian's VRDN-001.
Tickers: HZNP, VRDN, IMVT
Executed On: May 23, 2023 at 05:30 PM EDT
Upcoming & Overdue Catalysts (IMVT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IMVT)
Strategic Initiatives (IMVT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
